The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Cleveland Clinic researchers have discovered that just about two-thirds of sufferers with HER2-positive metastatic breast most cancers didn't obtain the guideline-recommended normal...
Researchers have introduced data revealing how sufferers with metastatic breast most cancers develop resistance to the therapy Enhertu (trastuzumab deruxtecan, T-DXd) in...
This years 2026 ASCO Gastrointestinal Cancers Symposium was full of practice-shaping knowledge throughout colorectal and higher gastrointestinal malignancies, in line with Dr....
